Herantis Pharma granted almost €3 million government loan for Parkinson’s study

News

Author: Parkinson's Life editorsPublished: 15 August 2015

Prep: Cook: Serves:

Tekes, the Finnish Funding Agency for Innovation, has granted a €2,903,000 loan to Herantis Pharma Plc to support its clinical study of CDNF for the treatment of Parkinson’s disease. The loan was granted conditionally, subject to obtaining regulatory approval for the clinical study.

Pekka Simula, CEO of Herantis Pharma, added: “We are very excited about our opportunity to translate the results of years of leading academic research to clinical stage, hopefully for the benefit of as many patients as possible.”

Herantis aims to start its clinical development programme with regulatory submissions in Finland and Sweden by the end of 2015. Patient treatments are expected to begin in the first half of 2016. The company expects to recruit 18 patients with Parkinson’s disease in this first-in-human study of CDNF.

Last Month

Next Month

Go Back

Share this story

Comments

Women and Parkinson's

“It’s so important to be clear about how people can help you”

Ingrid Roesner on speaking up with Parkinson’s disease

Chris Mamo: 40,000 steps in 12 hours for Parkinson’s

The fundraiser who didn’t stop running for 12 hours

World Brain Day 2020: “join our bandwagon to end Parkinson’s”

From the high cost of medication to a delay in Parkinson’s treatment due

Is there a link between Parkinson’s disease and blood vessel dysfunction?

Scientists in Slovakia have investigated the link between blood vessel dysfunction and Parkinson’s – and found that dopamine agonists may have an impact. The team studied the function of the endothelium – a membrane which lines the heart and blood vessels and helps control blood fluidity – in 41 people with the condition and 41 people without. Endothelial function was then measured through a parameter that assessed how easily blood could flow through the vessels. The results showed that while more people with Parkinson’s had endothelial dysfunction compared to those without, the difference did not reach statistical significance. However, the researchers noted that the findings suggested “an association between smoking, dopamine agonists, and impaired endothelial function” in those with the condition. Outlining the study’s limitations, the team noted that more research is needed to explore this potential link.

New swab test may help with Parkinson’s disease diagnosis

Researchers at the University of Manchester, UK, have drawn on one woman’s sense of smell to develop a swab test that may be used to detect Parkinson’s. The scientists used the test to analyse sebum (a type of oily substance on the skin) in 79 people with Parkinson’s and a control group of 71 healthy individuals. The team identified more than 4,000 different compounds in the participant samples – including 500 that were unique to those living with the condition. The test was developed with the help of Joy Milne from Perth, Scotland, whose unique sense of smell meant that she noticed a change in her late husband Les’s odour twelve years before he was diagnosed with Parkinson’s. Speaking to the BBC, Professor Perdita Barran, who led the research, described the test as potentially “transformative” – and said that the team hopes to roll the test out to people in…

Could a national biobank help inform the future of Parkinson’s disease treatment in Australia?

A biobank is a collection of biological samples and data designed to be used for research. Now, researchers in Australia are working to build a biobank for Parkinson’s. As part of the project, the scientists are conducting scans of people that have been injected with fluorodopa – a substance that highlights dopamine in the brain. Participants include people living with Parkinson’s and a control group of people without the condition. The resulting database of scans will be used to create a national biobank that aims to inform treatment and research into the condition. Commenting on the study, Olivia Nasser – executive director at the Hospital Research Foundation, which is helping to fund the research – said, “Once we build up the biobank of scans, it can actually be used as an effective way to treat Parkinson’s.” The researchers encourage people with and without Parkinson’s to take part in the trial.

All fields required

First name*
Last name*
Email address*
Enter Email Confirm Email
Country of residence*
About me*
- I have Parkinson's disease
- I am a partner / carer / family / friend of someone who has Parkinson's
- I am a healthcare professional with an interest in Parkinson's
- I work for a Parkinson's disease organisation
- Other
CAPTCHA
*
- By proceeding you agree to our
Phone
This field is for validation purposes and should be left unchanged.

Herantis Pharma granted almost €3 million government loan for Parkinson’s study

News

Author: Parkinson's Life editorsPublished: 15 August 2015

Prep: Cook: Serves:

Last Month

Next Month

Share this story

Comments

Women and Parkinson's

“It’s so important to be clear about how people can help you”

Interviews

Chris Mamo: 40,000 steps in 12 hours for Parkinson’s

Global update

World Brain Day 2020: “join our bandwagon to end Parkinson’s”

Is there a link between Parkinson’s disease and blood vessel dysfunction?

New swab test may help with Parkinson’s disease diagnosis

Could a national biobank help inform the future of Parkinson’s disease treatment in Australia?

{title}

Subscribe

Herantis Pharma granted almost €3 million government loan for Parkinson’s study

News

Author: Parkinson's Life editorsPublished: 15 August 2015

Last Month

Next Month

Share this story

Comments

Related articles

Women and Parkinson's

“It’s so important to be clear about how people can help you”

Interviews

Chris Mamo: 40,000 steps in 12 hours for Parkinson’s

Global update

World Brain Day 2020: “join our bandwagon to end Parkinson’s”

Is there a link between Parkinson’s disease and blood vessel dysfunction?

New swab test may help with Parkinson’s disease diagnosis

Could a national biobank help inform the future of Parkinson’s disease treatment in Australia?

{title}

Subscribe

Sign in